Perioperative durvalumab in addition to neoadjuvant chemotherapy shows positive results in patients with stage IIIa(N2) NSCLC

Pembrolizumab plus cCRT continue to demonstrate antitumour activity in advanced NSCLC

Treatment with BAY 2927088 led to durable responses in patients previously treated HER2-mutant NSCLC

Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced

Consolidation durvalumab after cCRT shows decreased disease progression in LS-SCLC

Subcutaneous pembrolizumab is a viable treatment option for mNSCLC

Recognising Excellence: The Vanessa Moss Prize - A Step Towards Equity in Global Health

Addition of radical prostatectomy to systemic treatment improves survival in oligometastatic prostate cancer

NeuroSAFE-guided RARP improves surgical precision for patients with localised prostate cancer

The added value of integrative medicine

Urine test could reduce post-op scans for kidney cancer by half

Micro-ultrasound is as effective as MRI in detecting prostate cancer